586 Folate Hydrolase-1 is a novel target for J591-brachytherapy in Merkel cell carcinoma
Folate Hydrolase-1 (FOLH1) is a type II transmembrane protein. Oncologically, FOLH1 is upregulated throughout prostate cancer cells; it is also luminally expressed by the neovasculature of most solid tumors but not by normal vessels. J591, a monoclonal antibody (AB), is specific to, and is effectively endocytosed after extracellular binding to, FOLH1. J591 is presently being developed in clinical trials as a vehicle for AB-based brachytherapy in FOLH1+ cancers. Merkel cell carcinoma (MCC) is a rare, neuroendocrine tumor; metastatic (m) MCC is associated with poor survival.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: M.K. Ramirez-Fort, B. Meier, K.S. Lachance, C.D. Church, C.S. Lange, L. French, P. Nghiem, N. Bander Tags: Melanoma and Other Skin Cancers Source Type: research
More News: Brachytherapy | Brain | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Dermatology | France Health | Melanoma | Merkel Cell Carcinoma | Neurology | Prostate Cancer | Skin | Skin Cancer